Duvelisib Delayed Progression in CLL/SLL: Study

Share this content:
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.

The dual inhibitor of PI3K-delta and PI3K-gamma, duvelisib, significantly improved progression-free survival (PFS) by more than 3 months compared with ofatumumab (median 13.3 months vs 9.9 months; hazard ratio [HR] = 0.52; P < .0001) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), according to results from the phase 3 DUO study.1

Most current therapies for CLL/SLL are not curative, leaving an urgent need for the development of new, effective treatment options. Duvelisib targets key signaling pathways involved in the growth and survival of hematologic malignancies.

In this phase 3 study, 319 patients were randomly assigned to receive treatment with oral duvelisib 25 mg twice daily (160 individuals) or to IV ofatumumab (159 individuals).

At a median follow-up of 22.4 months, the median PFS (judged per an Independent Review Committee) was 13.3 months for duvelisib compared with 9.9 months for ofatumumab (HR = 0.52; P < .0001). Duvelisib also significantly improved PFS in patients with high-risk chromosome 17p13.1 deletions (del[17p]) and/or TP53 mutations (HR = 0.40; P = .0001).

Treatment with duvelisib resulted in an overall response rate of 74% compared with 45% for ofatumumab (P < .0001), regardless of del(17p) status.

Patients assigned to receive duvelisib had approximately twice the treatment exposure. The most common adverse events associated with duvelisib and ofatumumab were neutropenia, anemia, and thrombocytopenia, as well as diarrhea, pyrexia, nausea, and cough.

Based on the trial results, the researchers concluded that “duvelisib monotherapy may offer an effective treatment for CLL/SLL patients in need of additional therapeutic options.”

Reference

  1. Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL [published online October 4, 2018]. Blood. doi: 10.1182/blood-2018-05-850461

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs